Umeclidinium in patients with COPD: A randomised, placebo-controlled study

European Respiratory Journal

Volumn 43, Issue 1, 2014, Pages 72-81

  Trivedi, Roopa ^a   Richard, Nathalie ^a   Mehta, Rashmi ^a   Church, Alison ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; PLACEBO; UMECLIDINIUM;

ADULT; BACKACHE; BURSITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY THROAT; DYSPHAGIA; DYSPHONIA; DYSPNEA; FEMALE; FEVER; FIRST DEGREE ATRIOVENTRICULAR BLOCK; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HEALTH STATUS; HEART ATRIUM FIBRILLATION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERTENSION; INCIDENCE; INHALER; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; OROPHARYNX PAIN; PARALLEL DESIGN; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOPHARYNGITIS; SCORING SYSTEM; SPIROMETRY; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; VISUAL HALLUCINATION;

ADMINISTRATION, INHALATION; AGED; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES; SMOKING; TREATMENT OUTCOME;

EID: 84891919272     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00033213     Document Type: Review

References (26)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. www.goldcopd.org/uploads/users/files/GOLD-Report-2011- Feb21.pdf. Date last updated: 2011. Date last accessed: June 4, 2013.
2. Jones PW, Rennard SI, Agusti A, et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res 2011; 12: 55.
3. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
4. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404.
5. Chan CK, Maltais F, Sigouin C, et al. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can Respir J 2007; 14: 465-472.
6. Church A, Beerahee M, Brooks J, et al. Umeclidinium (GSK573719) dose response and dosing interval in COPD. Eur Respir J 2012; 40: Suppl. 56, 377.
7. Donohue JF, Anzueto A, Brooks J, et al. A randomized, double-blind, dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med 2012; 106: 970-979.
8. Decramer M, Maltais F, Feldman G, et al. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol 2013; 185: 393-399.
9. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
10. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159: 179-187.
11. Hankinson JL, Kawut SM, Shahar E, et al. Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: The multi-ethnic study of atherosclerosis (MESA) lung study. Chest 2010; 137: 138-145.
12. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended (latest) by the 59th WMA General Assembly, Seoul, Korea, October 2008. www.wma.net/en/30publications/10policies/b3/index.html Date last updated: October 2008. Date last accessed: June 4, 2013.
13. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). ICH Good Clinical Practice guidelines. www.ich.org/products/guidelines/efficacy/efficacysingle/article/ good-clinical-practice.html Date last accessed: November 6, 2013.
14. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-758.
15. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-1327.
16. Miller MR, Hankinson J, Brusasco V, et al. Standardisation for spirometry. Eur Respir J 2005; 26: 319-338.
17. Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD 2005; 2: 99-103.
18. Jones PW. St George's Respiratory Questionnaire: MCID. COPD 2005; 2: 75-79.
19. Cahn A, Lovick R, Newlands A, et al. Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 in healthy subjects. Eur Respir J 2011; 38: Suppl. 55, 723.
20. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: From lung function to biomarkers. Eur Respir J 2008; 31: 416-469.
21. Donohue JF, van Noord JA, Bateman ED, et al. 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.
22. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ 2000; 320: 1297-1303.
23. Kerwin EM, D'Urzo AD, Gelb AF, et al. ACCORD I study investigators. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012; 9: 90-101.
24. Kerwin EM, Gotfried MH, Lawrence D, et al. Efficacy and tolerability of indacaterol 75 mg once daily in patients aged o40 years with chronic obstructive pulmonary disease: Results fromm double-blind, placebo-controlled 12-week studies. Clin Ther 2011; 33: 1974-1984.
25. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD duringgyr's treatment with tiotropium. Eur Respir J 2002; 19: 209-216.
26. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224.